The long-term efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine in patients with medication overuse: results of the COMPEL study

被引：0
|
作者：
Tepper, S. [1 ]
Wilson, M. -C. [2 ]
Orejudos, A. [3 ]
Adams, A. Manack [3 ]
Blumenfeld, A. [4 ]
机构：
[1] Geisel Sch Med Dartmouth, Hanover, NH USA
[2] Ochsner Hlth Syst, Covington, LA USA
[3] Allergan Plc, Irvine, CA USA
[4] Headache Ctr Southern Calif, Neurol Cente, Carlsbad, CA USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2018年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O404
引用
收藏
页码：78 / 78
页数：1
相关论文
共 50 条
  • [41] Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse
    Ahmed, Fayyaz
    Zafar, Hassan W.
    Buture, Alina
    Khalil, Modar
    SPRINGERPLUS, 2015, 4
  • [42] Long-term effectiveness of eptinezumab in treatment of patients with chronic migraine and medication-overuse headache
    Blumenfeld, A.
    Kudrow, D.
    McAllister, P.
    Boserup, L.
    Hirman, J.
    Cady, R.
    HEADACHE, 2023, 63 : 145 - 145
  • [43] Long-term effectiveness of eptinezumab in treatment of patients with chronic migraine and medication-overuse headache
    Blumenfeld, A.
    Kudrow, D.
    McAllister, P.
    Boserup, L.
    Hirman, J.
    Cady, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 375 - 376
  • [44] Long-term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication-overuse headache
    Blumenfeld, Andrew
    Kudrow, David
    Mcallister, Peter
    Boserup, Line Pickering
    Hirman, Joe
    Cady, Roger
    HEADACHE, 2024, 64 (07): : 738 - 749
  • [45] Reply: OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine
    Pijpers, Judith A.
    Ferrari, Michel D.
    Terwindt, Gisela M.
    BRAIN, 2020, 143
  • [46] Long-term adherence, safety, and efficacy of repeated onabotulinumtoxinA over five years in chronic migraine prophylaxis
    Argyriou, Andreas A.
    Dermitzakis, Emmanouil, V
    Vlachos, George S.
    Vikelis, Michail
    ACTA NEUROLOGICA SCANDINAVICA, 2022, 145 (06): : 676 - 683
  • [47] Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy (vol 8, 586, 2017)
    Guerzoni, Simona
    Pellesi, Lanfranco
    Baraldi, Carlo
    Cainazzo, Michela Maria
    Negro, Andrea
    Martelletti, Paolo
    Pini, Luigi Alberto
    FRONTIERS IN NEUROLOGY, 2018, 9
  • [48] ONABOTULINUMTOXINA IS WELL TOLERATED IN CHRONIC MIGRAINE PATIENTS TAKING ORAL PREVENTIVE MEDICATIONS: LONG-TERM COMPEL ANALYSIS BY TREATMENT CYCLE
    Winner, Paul K.
    Blumenfeld, Andrew M.
    Eross, Eric J.
    Orejudos, Amelia
    Adams, Aubrey Manack
    Brin, Mitchell F.
    TOXICON, 2018, 156 : S114 - S114
  • [49] Efficacy and safety of onabotulinumtoxinA in pediatric patients with chronic migraine
    Caronna, E.
    Mas-de-les-Valls-Cerco, R.
    Gallardo, V. J.
    Gomez-Dabo, L.
    Alpuente, A.
    Torres-Ferrus, M.
    Pozo-Rosich, P.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [50] Healthcare Resource Utilization in Adult Patients Treated with OnabotulinumtoxinA for Chronic Migraine: Results from the COMPEL Study
    Rothrock, J. F.
    Stark, R.
    Sommer, K.
    Blumenfeld, A. M.
    HEADACHE, 2019, 59 : 108 - 109
12345